Stay updated on Tagraxofusp in Secondary AML Clinical Trial
Sign up to get notified when there's something new on the Tagraxofusp in Secondary AML Clinical Trial page.

Latest updates to the Tagraxofusp in Secondary AML Clinical Trial page
- Check3 days agoChange DetectedThe history section now includes new entries for eligibility and study status, with a latest version noted as 27 around 2026-07-09 and an entry for 2026-07-10; an older entry from 2026-04-08 has been removed.SummaryDifference0.4%

- Check10 days agoChange DetectedRevision label updated to v3.6.3 in the page history, replacing the previous v3.6.2. This reflects a minor update to the page rendering or metadata for the study record, without changes to the study data.SummaryDifference0.1%

- Check18 days agoChange DetectedThe page history now shows Revision: v3.6.2, replacing the previous v3.6.0. This reflects an update to the record history’s versioning metadata.SummaryDifference0.1%

- Check32 days agoChange DetectedAdded Check who can join and Find Contact Information, plus a Revision: v3.6.0 note in the history view. These updates reflect UI and documentation changes that improve access to recruitment information and staff contact details, while recording the latest platform release.SummaryDifference0.4%

- Check39 days agoChange DetectedAn updated revision tag has been added to the history, changing from v3.5.4 to v3.5.5 to reflect an administrative update to the record. This change does not affect the study content or functionality, but records the latest version of the record in ClinicalTrials.gov history.SummaryDifference0.1%

- Check54 days agoChange DetectedA new version entry was added to the study record history, including updated study status entries and refreshed contacts/locations. This reflects ongoing administrative and recruitment updates to the trial.SummaryDifference0.1%

Stay in the know with updates to Tagraxofusp in Secondary AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tagraxofusp in Secondary AML Clinical Trial page.